<SEC-DOCUMENT>0001104659-25-054587.txt : 20250530
<SEC-HEADER>0001104659-25-054587.hdr.sgml : 20250530
<ACCEPTANCE-DATETIME>20250530083023
ACCESSION NUMBER:		0001104659-25-054587
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20250530
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20250530
DATE AS OF CHANGE:		20250530

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GLYCOMIMETICS INC
		CENTRAL INDEX KEY:			0001253689
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36177
		FILM NUMBER:		251006649

	BUSINESS ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		240-243-1201

	MAIL ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2516580d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:GLYC="http://glycomimetics.com/20250530">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_GLYC_glycomimetics.com_20250530 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20250530_20250530 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05B_edei%2D%2DEntityCentralIndexKey_0001253689 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-05-30" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-05-30" id="Fact000004" name="dei:EntityCentralIndexKey">0001253689</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="glyc-20250530.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-05-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-30</xbrli:startDate>
        <xbrli:endDate>2025-05-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_902_edei--DocumentType_c20250530__20250530_zGUaM2OMROc6"><ix:nonNumeric contextRef="AsOf2025-05-30" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event reported):&#160;<span id="xdx_909_edei--DocumentPeriodEndDate_c20250530__20250530_zV9Nr7WuoXq5"><ix:nonNumeric contextRef="AsOf2025-05-30" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">May
30, 2025</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_900_edei--EntityRegistrantName_c20250530__20250530_z9ZQjQAJqx9b"><b><ix:nonNumeric contextRef="AsOf2025-05-30" id="Fact000011" name="dei:EntityRegistrantName">GlycoMimetics,
Inc.</ix:nonNumeric></b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of Registrant as Specified in
Its Charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 32%">&#160;</td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 32%">&#160;</td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 32%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><b><span id="xdx_90B_edei--EntityIncorporationStateCountryCode_c20250530__20250530_zrreswFhsyxc" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-05-30" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_900_edei--EntityFileNumber_c20250530__20250530_zZFu4yWmOPi4" style="font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2025-05-30" id="Fact000013" name="dei:EntityFileNumber">001-36177</ix:nonNumeric></b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_90D_edei--EntityTaxIdentificationNumber_c20250530__20250530_z4YtkOSk45e3" style="font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2025-05-30" id="Fact000014" name="dei:EntityTaxIdentificationNumber">06-1686563</ix:nonNumeric></b></span></td></tr>
  <tr style="font-weight: bold">
    <td style="font-weight: bold; vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>(State or Other Jurisdiction
    of Incorporation)</b></span></td>
    <td style="font-weight: bold; vertical-align: bottom"><b>&#160;</b></td>
    <td style="font-weight: bold; vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>(Commission File Number)</b></span></td>
    <td style="font-weight: bold; vertical-align: bottom"><b>&#160;</b></td>
    <td style="font-weight: bold; vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>(IRS Employer<br/>
    Identification No.)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_900_edei--EntityAddressAddressLine1_c20250530__20250530_zLkGzC347lhi"><b><ix:nonNumeric contextRef="AsOf2025-05-30" id="Fact000015" name="dei:EntityAddressAddressLine1">P.O.
Box 65</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_903_edei--EntityAddressCityOrTown_c20250530__20250530_zaLVr5f2IrO1"><b><ix:nonNumeric contextRef="AsOf2025-05-30" id="Fact000016" name="dei:EntityAddressCityOrTown">Monrovia</ix:nonNumeric></b></span><b>,
<span id="xdx_904_edei--EntityAddressStateOrProvince_c20250530__20250530_zq72bBBnedLf"><ix:nonNumeric contextRef="AsOf2025-05-30" format="ixt-sec:stateprovnameen" id="Fact000017" name="dei:EntityAddressStateOrProvince">Maryland</ix:nonNumeric></span></b><b>&#160;<span id="xdx_909_edei--EntityAddressPostalZipCode_c20250530__20250530_zaRDarr4Yrfb"><ix:nonNumeric contextRef="AsOf2025-05-30" id="Fact000018" name="dei:EntityAddressPostalZipCode">21770</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices, including
zip code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_90A_edei--CityAreaCode_c20250530__20250530_zCsnD3ssSVu4"><ix:nonNumeric contextRef="AsOf2025-05-30" id="Fact000019" name="dei:CityAreaCode">240</ix:nonNumeric></span></b><b>)
<span id="xdx_90B_edei--LocalPhoneNumber_c20250530__20250530_zPrgMiTvXvAh"><ix:nonNumeric contextRef="AsOf2025-05-30" id="Fact000020" name="dei:LocalPhoneNumber">243-1201</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including
area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.25pt; text-indent: -14.25pt"><span id="xdx_90D_edei--WrittenCommunications_c20250530__20250530_zNbXuLHmqOze" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2025-05-30" format="ixt:booleantrue" id="Fact000021" name="dei:WrittenCommunications">x</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif">&#160;</span>Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.25pt; text-indent: -14.25pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.25pt; text-indent: -14.25pt"><span id="xdx_90F_edei--SolicitingMaterial_c20250530__20250530_zmIZp1wKyNJ1" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2025-05-30" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif">&#160;</span>Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.25pt; text-indent: -14.25pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.25pt; text-indent: -14.25pt"><span id="xdx_906_edei--PreCommencementTenderOffer_c20250530__20250530_zkzdLCujQq6h" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2025-05-30" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif">&#160;</span>Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.25pt; text-indent: -14.25pt"><span id="xdx_909_edei--PreCommencementIssuerTenderOffer_c20250530__20250530_zrGutjKqBX0h" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2025-05-30" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span>
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Securities registered
pursuant to Section 12(b) of the Act:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding-right: 5.65pt; padding-left: 5.65pt">&#160;</td>
    <td style="padding-right: 5.65pt; padding-left: 5.65pt">&#160;</td>
    <td style="padding-right: 5.65pt; padding-left: 5.65pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; padding-top: 5pt; padding-bottom: 5pt; text-align: center"><span style="font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 5pt; padding-bottom: 5pt; text-align: center"><span style="font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 5pt; padding-bottom: 5pt; text-align: center"><span style="font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 5pt; padding-bottom: 5pt; text-align: center"><span id="xdx_90D_edei--Security12bTitle_c20250530__20250530_zt1HxR7ZGy3k" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-05-30" id="Fact000025" name="dei:Security12bTitle">Common
    Stock, $0.001 par value</ix:nonNumeric></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 5pt; padding-bottom: 5pt; text-align: center"><span id="xdx_908_edei--TradingSymbol_c20250530__20250530_zyqmLm2ugyc9" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-05-30" id="Fact000026" name="dei:TradingSymbol">GLYC</ix:nonNumeric></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 5pt; padding-bottom: 5pt; text-align: center"><span id="xdx_908_edei--SecurityExchangeName_c20250530__20250530_zFZdQ2JwrBS2" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-05-30" format="ixt-sec:exchnameen" id="Fact000027" name="dei:SecurityExchangeName">The
    Nasdaq Stock Market</ix:nonNumeric></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span id="xdx_909_edei--EntityEmergingGrowthCompany_c20250530__20250530_zTf3mX88Qx59" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2025-05-30" format="ixt:booleanfalse" id="Fact000028" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 1in"><b>Item 8.01</b></td>
    <td style="font-size: 10pt"><b>Other Events.</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As previously disclosed, GlycoMimetics, Inc.,
a Delaware corporation (&#8220;GlycoMimetics&#8221;), entered into an Agreement and Plan of Merger and Reorganization, dated October
28, 2024, which agreement was amended on February 14, 2025 and April 28, 2025 (as amended, the &#8220;Merger Agreement&#8221;), with
Gemini Merger Sub Corp., a Delaware corporation and a wholly-owned subsidiary of GlycoMimetics (&#8220;First Merger Sub&#8221;), Gemini
Merger Sub II, LLC, a Delaware limited liability company and wholly-owned subsidiary of GlycoMimetics (&#8220;Second Merger Sub&#8221;
and, together with First Merger Sub, &#8220;Merger Subs&#8221;), and Crescent Biopharma, Inc., a Delaware corporation (&#8220;Crescent&#8221;).
The Merger Agreement provides that, upon the terms and subject to the conditions set forth therein, First Merger Sub, will merge with
and into Crescent, with Crescent continuing as a wholly owned subsidiary of GlycoMimetics and the surviving corporation of the merger
(the &#8220;First Merger&#8221;), and Crescent will merge with and into Second Merger Sub (the &#8220;Second Merger&#8221; and, together
with the First Merger, the &#8220;Merger&#8221;), with Second Merger Sub being the surviving entity of the Second Merger. After the completion
of the Merger, Second Merger Sub will change its corporate name to &#8220;Crescent Biopharma Operating Company, LLC&#8221; and GlycoMimetics
will change its name to &#8220;Crescent Biopharma, Inc.&#8221; The Merger Agreement was unanimously approved by the board of directors
of each of GlycoMimetics and Crescent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Merger, GlycoMimetics
filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) a registration statement on Form S-4, which includes a proxy
statement/prospectus (the &#8220;Form S-4&#8221;), most recently amended on May 12, 2025 and declared effective by the SEC on May 14,
2025. GlycoMimetics and Crescent commenced mailing of the definitive proxy statement/prospectus on May 14, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following supplemental disclosures should
be read in conjunction with the Form S-4, which should be read in its entirety as supplemented. The inclusion in this supplement to the
Form S-4 of certain information should not be regarded as an indication that any of GlycoMimetics or its directors, affiliates, officers,
or other representatives, or any other recipient of this information, considered, or now considers, it to be material, and such information
should not be relied upon as such. Defined terms used but not defined herein have the meanings set forth in the Form S-4. For clarity,
new text within restated paragraphs from the Form S-4 is highlighted with <b><span style="text-decoration: underline">bold, underlined text</span></b>, and deleted text within
restated paragraphs from the Form S-4 is highlighted with <span style="text-decoration: line-through">strikethrough text</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The disclosure under the heading &#8220;<i>Background
of the Merger</i>&#8221; is hereby amended and supplemented by replacing the second and third paragraphs beginning on page 121 of the
Form S-4 in their entirety with the following:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following receipt of bid letters on August 21,
2024, Lucid reviewed the proposals and selected 11 potential counterparties that most strongly aligned with GlycoMimetics&#8217; <span style="text-decoration: line-through">stated</span>
requirements <span style="text-decoration: line-through">and projected closing cash levels</span> <b><span style="text-decoration: underline">regarding time to closing, ability to raise capital and the need
for and amount of a concurrent financing, likelihood of closing and the amount of cash that GlycoMimetics would be required to have as
of the closing date</span></b>. Lucid engaged in discussions with each of the 11 finalists to assess their interest in moving forward with
a potential transaction and based on those conversations, identified that 5 of the 11 potential counterparties would be interested in
presenting to GlycoMimetics&#8217; management. Based on discussions with the management of GlycoMimetics regarding GlycoMimetics&#8217;
updated expense budgets and anticipated cash forecasts through the potential closing of a reverse merger transaction, Lucid reprioritized
discussions with the potential counterparties to focus on 10 candidates believed to be most interested in and reasonably able to consummate
a reverse merger with GlycoMimetics. After diligence calls with each of these 10 counterparties, three viable targets were identified
and the <span style="text-decoration: line-through">remaining</span> <b><span style="text-decoration: underline">other</span></b> seven potential counterparties were deprioritized <span style="text-decoration: line-through">due to transactability
issues, including cash needs, milestone timing, free float considerations, and valuation concerns</span> <b><span style="text-decoration: underline">for the reasons listed
above, with a particular focus on the inability to raise the necessary funds for a concurrent financing</span></b>. GlycoMimetics&#8217;
management reviewed with Lucid the non-binding proposals provided by the three remaining potential counterparties and, during the week
of September 2, 2024, met with representatives of each potential counterparty. Following the counterparty management presentations and
after further diligence, Lucid worked with GlycoMimetics&#8217; management to refine GlycoMimetics&#8217; estimate of <span style="text-decoration: line-through">closing</span>
<b><span style="text-decoration: underline">its</span></b> cash <span style="text-decoration: line-through">deliverable at a</span> <b><span style="text-decoration: underline">on</span></b> projected closing <span style="text-decoration: line-through">and determined that two of the three
potential counterparties would not be</span> <b><span style="text-decoration: underline">dates, and two parties remained</span></b> viable choices<b><span style="text-decoration: underline">: Crescent; and another
potential counterparty, &#8220;Party A&#8221;</span></b>. With respect to <b><span style="text-decoration: underline">Party A</span></b> <span style="text-decoration: line-through">the remaining potential counterparty
(&#8220;Party A&#8221;)</span>, on September 10, 2024, GlycoMimetics&#8217; management directed Lucid to present Party A with a proposed
term sheet for a reverse merger reflecting, among other items, the anticipated closing cash deliverable by GlycoMimetics and a reduced
equity valuation for Party A. Thereafter, on September 12, 2024, Party A presented a further revised proposed term sheet with additional
proposed revisions, including a readjusted Party A valuation.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: line-through">Following the announcement of topline
results</span> <b><span style="text-decoration: underline">Throughout this period</span></b>, GlycoMimetics&#8217; management continued to explore potential monetization transactions
for GlycoMimetics&#8217; other programs, but was unable to identify any other viable transactions. On September 5, 2024, following extensive
marketing efforts and discussion with multiple potentially interested parties, GlycoMimetics sold its rivipansel program to Biossil Inc.
for approximately $1 million in cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The disclosure under the heading &#8220;<i>Background
of the Merger</i>&#8221; is hereby amended and supplemented by replacing the final paragraph beginning on page 122 and carrying over
onto page 123 of the Form S-4 in its entirety with the following:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following Crescent&#8217;s presentation, the
GlycoMimetics Board determined that Crescent was a counterparty that merited serious consideration because (i) it required a minimal
amount of GlycoMimetics&#8217; cash and would therefore allow for sufficient time to complete the proposed transaction, (ii) the company
was backed by a reputable investor with a history of successful reverse merger transactions, and (iii) the company was confident that
it could secure strong interest with respect to an investment that would be contemplated to close concurrently with the closing of the
proposed merger. As a result, the GlycoMimetics Board focused its efforts on pursuing a transaction with Crescent while continuing to
discuss a potential transaction with Party A in case a transaction with Crescent did not come to fruition. The GlycoMimetics Board determined
that it should pursue a transaction with Crescent in light of the GlycoMimetics Board&#8217;s view that (i) the liquidation of GlycoMimetics
was not reasonably likely to result in superior value to GlycoMimetics&#8217; stockholders when compared to the proposed transaction;
(ii) the $8 million enterprise value ascribed to GlycoMimetics would give GlycoMimetics&#8217; stockholders a significant opportunity
to participate in the potential growth of the Combined Company following the merger at the negotiated exchange ratio; (iii) the preliminary
due diligence performed to date and the recommendations of its advisors with respect to the viability of Crescent&#8217;s assets, including
the proposed concurrent $125 million PIPE financing, would provide a meaningful opportunity to GlycoMimetics&#8217; stockholders; (iv)
the likelihood of consummation of the proposed transaction would be high given Paragon licensees&#8217; recent record of successful reverse
merger transactions and substantial capital resources; and (v) the proposal from Crescent was more favorable to GlycoMimetics than the
potential value that might have resulted from further pursuing other strategic transactions available to GlycoMimetics, including with
Party A, in light of the extensive outreach process undertaken to date. To assist with the potential transaction, the GlycoMimetics Board
discussed the establishment of a special transaction committee for the purpose of reviewing, negotiating and making recommendations to
the GlycoMimetics Board regarding subsequent changes to the Crescent Term Sheet (the &#8220;Term Sheet Committee&#8221;). The Term Sheet
Committee was formed for convenience of the. GlycoMimetics Board and not because of any conflicts-related concerns with Crescent or Paragon.
The GlycoMimetics Board approved the formation of the Term Sheet Committee and appointed Mr. Junius and Mr. Pearson to serve on the Term
Sheet Committee. The GlycoMimetics Board delegated to the Term Sheet Committee the full power and authority of the GlycoMimetics Board
to, among other things, consider, evaluate, negotiate and make recommendations to the GlycoMimetics Board regarding the Crescent Term
Sheet. It was also discussed and concluded that the Term Sheet Committee would update and seek input from the GlycoMimetics Board as
appropriate; and members of the GlycoMimetics Board who were not also members of the Term Sheet Committee would have timely access to
the Crescent Term Sheet and any subsequent changes thereto. <b><span style="text-decoration: underline">The members of the Term Sheet Committee received no additional compensation
for this assignment and the Term Sheet Committee was formally dissolved on October 28, 2024, immediately after the Company executed the
Merger Agreement with Crescent.</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>The disclosure under the heading &#8220;<i>Background of the Merger</i>&#8221;
is hereby amended and supplemented by replacing the first paragraph beginning on page 123 of the Form S-4 in its entirety with the following:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 19, 2024 and September 20, 2024,
GlycoMimetics&#8217; management and the legal representatives and financial advisors to each of GlycoMimetics and Crescent continued
to perform due diligence on Crescent and the potential strategic opportunity and held multiple discussions regarding, among other things,
the form of the proposed transaction and related timelines; Crescent&#8217;s proposed increase of the level of concurrent PIPE financing
with no concomitant change to GlycoMimetics valuation; the proposed development plan for Crescent&#8217;s technology and the indication
under development; the potential contribution of additional assets to Crescent, including GlycoMimetics&#8217; existing pipeline; the
substantive economic terms of a potential reverse merger transaction; and the relative valuations to be ascribed to each party. Following
these discussions, a revised Crescent Term Sheet was circulated to the Term Sheet Committee for approval, which was granted. Thereafter,
on the evening of September 20, 2024, Lucid delivered a revised draft of the Crescent Term Sheet to Wedbush, proposing a reverse merger
transaction ascribing an $8,000,000 enterprise valuation to GlycoMimetics, a $50,000,000 enterprise valuation of Crescent, a concurrent
PIPE financing in the amount of $125,000,000, and setting forth certain other material terms including (1) conditions to execution of
any definitive agreement, (2) conditions to the closing of the business combination transaction; and (3) the exclusivity period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">During a diligence update call held on
September 12, 2024, Crescent informed GlycoMimetics and representatives of Lucid that Crescent did not plan to retain, employ or otherwise
engage any GlycoMimetics executives after the closing of the proposed merger. During a follow-up call on October 16, 2024, Crescent reaffirmed
that position and further confirmed that the transaction structure contemplated no equity roll-over, retention equity or other employment-linked
consideration for GlycoMimetics&#8217; management team.</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The disclosure under the heading &#8220;<i>Background
of the Merger</i>&#8221; is hereby amended and supplemented by replacing the second to last paragraph beginning on page 123 of the Form
S-4 in its entirety with the following:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 24, 2024, GlycoMimetics made the
decision not to pursue a transaction with Party A. Party A is owned by a Chinese parent and GlycoMimetics was concerned about the unknown
time it would take for Chinese regulatory bodies to clear the transaction. <b><span style="text-decoration: underline">The GlycoMimetics Board also confirmed at this meeting&#8212;after
consultation with management and Lucid&#8212;that, given the going-concern uncertainties described in Note 1 to GlycoMimetics&#8217;
audited financial statements, it was not feasible to prepare financial projections and they would not be meaningful for use in evaluating
the proposed merger or any alternative transaction. Additionally, no financial projections prepared by or on behalf of Crescent were
provided to GlycoMimetics or Lucid at any time.</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The disclosure under the heading &#8220;<i>Background
of the Merger</i>&#8221; is hereby amended and supplemented by replacing the second paragraph beginning on page 124 of the Form S-4 in
its entirety with the following:</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Between July 2023 and September 2024, GlycoMimetics
entered into 14 confidentiality agreements with prospective counterparties, including biotechnology companies, discovery platforms and
life-science investors, one of which was Paragon. 12 of these confidentiality agreements, including the one with Paragon, contained standstill
provisions restricting the counterparty from acquiring GlycoMimetics securities or pursuing a control transaction which included &#8220;don&#8217;t-ask,
don&#8217;t-waive&#8221; language that prohibited the counterparty from requesting a waiver of the standstill. These provisions automatically
terminated in accordance with their terms upon the signing of the Merger Agreement.</span></b> On October 16, 2024, GlycoMimetics executed
an indemnity letter with Jefferies LLC, TD Securities (USA) LLC and Stifel, Nicolaus &amp; Company, Incorporated as placement agents
in respect of the sale of securities underlying the proposed $125 million concurrent PIPE financing.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The disclosure under the heading &#8220;<i>Selected
Precedent IPO Companies&#8221;</i> is hereby amended and supplemented by replacing the table on page 137 of the Form S-4 in its entirety
with the following:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; text-align: center; padding-bottom: 5pt; width: 14%; padding-right: 0; padding-left: 0; vertical-align: bottom">First-Trade
    Date &#160;</td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; width: 20%; padding-right: 0; padding-bottom: 5pt; padding-left: 0; vertical-align: bottom">Issuer</td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; width: 13%; padding-right: 0; padding-bottom: 5pt; padding-left: 0; vertical-align: bottom"><span style="text-decoration: underline solid; color: Black"><b>Stage
    at <br/>
    IPO</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; width: 13%; padding-right: 0; padding-bottom: 5pt; padding-left: 0; vertical-align: bottom"><span style="text-decoration: underline solid; color: Black"><b>Pre-Money<br/>
    Value ($m)</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; width: 13%; padding-right: 0; padding-bottom: 5pt; padding-left: 0; vertical-align: bottom"><span style="text-decoration: underline solid; color: Black"><b>Cash
    ($m)</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; width: 13%; padding-right: 0; padding-bottom: 5pt; padding-left: 0; vertical-align: bottom"><span style="text-decoration: underline solid; color: Black"><b>Debt
    ($m)</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; width: 14%; padding-right: 0; padding-bottom: 5pt; padding-left: 0; vertical-align: bottom"><span style="color: Black">Enterprise
    <br/>
    Value at IPO<br/>
    ($m)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">9/13/2024</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Bicara
    Therapeutics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    I</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>616.7</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>203.9</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>0.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">412.8</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">2/09/2024</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Adagene</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    I</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>853.3</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>75.2</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>8.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">786.1</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">7/21/2023</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Turnstone
    Biologics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    I</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>186.3</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>49.2</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>0.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">137.1</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">2/04/2022</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Nuvectis
    Pharma</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    I</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>47.6</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>5.7</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>0.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">41.9</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">1/13/2022</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Tharimmune</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Pre-clinical</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>29.9</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>0.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>2.2</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">32.1</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">10/22/2021</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Xilio
    Therapeutics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    I</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>309.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>99.8</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>9.6</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">218.8</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">10/07/2021</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Pyxis
    Oncology</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Pre-clinical</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>355.7</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>133.5</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>0.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">222.2</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">9/15/2021</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Tyra
    Biosciences</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Pre-clinical</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>481.8</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>135.2</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>0.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">346.6</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">7/29/2021</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Omega
    Therapeutics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Pre-clinical</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>668.5</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>122.4</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>11.8</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">557.9</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">6/17/2021</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Lyell
    Immunopharma</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Pre-clinical</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>3,703.1</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>604.9</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>0.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">3,098.2</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">6/11/2021</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Janux
    Therapeutics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Pre-clinical</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>484.5</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>70.7</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>0.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">413.8</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">5/04/2021</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Werewolf
    Therapeutics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Pre-clinical</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>320.6</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>84.6</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>0.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">236.0</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">2/04/2021</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Bolt
    Biotherapeutics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    I</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>460.4</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>22.8</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>0.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">437.6</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">9/25/2020</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Prelude
    Therapeutics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    I</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>648.5</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>29.7</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>0.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">618.8</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">8/14/2020</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">CureVac
    N.V.</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    I</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>2,602.2</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>49.3</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>67.1</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">2,619.9</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">7/16/2020</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Relay
    Therapeutics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    I</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>1,337.5</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>312.2</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>0.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">1,025.3</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">4/24/2020</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">ORIC
    Pharmaceuticals</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    I</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>340.7</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>79.4</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>0.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">261.3</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">1/30/2020</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Black
    Diamond Therapeutics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Pre-clinical</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>451.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>154.7</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>0.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">296.3</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">5/22/2019</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Bicycle
    Therapeutics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    I</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>187.1</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>59.4</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>0.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">127.7</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">9/27/2018</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Gritstone
    Bio</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    I</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>332.4</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>64.5</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>10.5</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt">278.4</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The disclosure under the heading &#8220;<i>Selected
Publicly Traded Companies</i>&#8221; is hereby amended and supplemented by replacing the table on page 138 of the Form S-4 in its entirety
with the following:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; background-color: White; vertical-align: bottom; text-align: center; width: 20%; padding-right: 0; padding-bottom: 5pt; padding-left: 0">Company</td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 13%; background-color: White; padding-right: 0; padding-bottom: 5pt; padding-left: 0"><span style="text-decoration: underline solid; color: Black"><b>Ticker</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 13%; background-color: White; padding-right: 0; padding-bottom: 5pt; padding-left: 0"><span style="text-decoration: underline solid; color: Black"><b>Stage</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 14%; background-color: White; padding-right: 0; padding-bottom: 5pt; padding-left: 0"><span style="text-decoration: underline solid; color: Black"><b>Market
    Cap<br/>
    ($m)</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 13%; background-color: White; padding-right: 0; padding-bottom: 5pt; padding-left: 0"><span style="text-decoration: underline solid; color: Black"><b>Debt
    ($m)</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 13%; background-color: White; padding-right: 0; padding-bottom: 5pt; padding-left: 0"><span style="text-decoration: underline solid; color: Black"><b>Cash
    ($m)</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: bottom; text-align: center; width: 14%; padding-right: 0; padding-bottom: 5pt; padding-left: 0"><span style="color: Black">Enterprise
    Value<br/>
    ($m)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Janux
    Therapeutics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>JANX</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    I</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>2,786.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>0.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>646.3</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">2,139.7</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Enliven
    Therapeutics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>ELVN</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    I</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>1,360.9</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>0.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>312.4</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">1,048.5</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Tyra
    Biosciences</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>TYRA</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    I</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>1,158.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>0.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>373.8</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">784.2</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Bicara
    Therapeutics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>BCAX</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    I</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>1,223.7</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>0.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>565.9</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">657.8</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Immatics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>IMTX</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    I</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>1,105.2</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>0.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>718.5</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">386.7</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">ORIC
    Pharmaceuticals</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>ORIC</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    I</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>574.9</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>0.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>308.5</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">266.4</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Instil
    Bio</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>TIL</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    I</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>202.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>81.9</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>148.8</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">135.2</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Mersana
    Therapeutics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>MRSN</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    I</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>233.1</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>25.4</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>162.7</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">95.7</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Context
    Therapeutics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>CNTX</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    I</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>175.5</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>0.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>101.5</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">74.0</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Corbus
    Pharmaceuticals</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>CRBP</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    I</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>196.4</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>10.8</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>147.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">60.2</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">TScan
    Therapeutics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>TCRX</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    I</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>257.5</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>30.4</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>297.7</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">(9.8)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Fate
    Therapeutics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>FATE</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    I</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>301.8</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>0.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>352.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">(50.2)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">CytomX
    Therapeutics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>CTMX</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    I</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>80.5</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>0.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>137.2</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt">(56.7)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The disclosure under the heading &#8220;<i>Selected
Publicly Traded Companies</i>&#8221; is hereby amended and supplemented by replacing the first table on page 139 of the Form S-4 in its
entirety with the following:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; background-color: White; text-align: center; width: 20%; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; vertical-align: bottom">Company</td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; width: 13%; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; vertical-align: bottom"><span style="text-decoration: underline solid; color: Black"><b>Ticker</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; width: 13%; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; vertical-align: bottom"><span style="text-decoration: underline solid; color: Black"><b>Stage</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; width: 14%; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; vertical-align: bottom"><span style="text-decoration: underline solid; color: Black"><b>Market
    Cap<br/>
    ($m)</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; width: 13%; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; vertical-align: bottom"><span style="text-decoration: underline solid; color: Black"><b>Debt
    ($m)</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; width: 13%; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; vertical-align: bottom"><span style="text-decoration: underline solid; color: Black"><b>Cash
    ($m)</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; text-align: center; width: 14%; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; vertical-align: bottom"><span style="color: Black">Enterprise<br/>
    Value ($m)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Apogee
    Therapeutics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>APGE</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    II</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>3,113.2</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>0.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>789.6</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">2,323.6</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Spyre
    Therapeutics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>SYRE</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    I</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>1,772.5</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>0.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>426.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">1,346.5</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Viridian
    Therapeutics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>VRDN</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    III</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>1,759.8</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>20.5</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>796.4</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">983.9</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Cogent
    Biosciences</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>COGT</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    III</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>1,310.1</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>0.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>389.9</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">920.2</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Oruka
    Therapeutics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>ORKA</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Pre-clinical</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>979.6</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>0.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>475.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">504.6</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Astria
    Therapeutics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>ATXS</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    Ib/II</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>647.2</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>0.0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>354.7</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt">292.5</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The disclosure under the heading &#8220;<i>Selected
Precedent M&amp;A Transactions</i>&#8221; is hereby amended and supplemented by replacing the second table on page 139 of the Form S-4
in its entirety with the following:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; background-color: White; text-align: center; width: 20%; padding-right: 0; padding-bottom: 5pt; padding-left: 0; vertical-align: bottom">Closed
    Date</td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; text-align: center; width: 22%; padding-right: 0; padding-bottom: 5pt; padding-left: 0; vertical-align: bottom">Target</td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; text-align: center; width: 20%; padding-right: 0; padding-bottom: 5pt; padding-left: 0; vertical-align: bottom">Acquirer</td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; width: 19%; background-color: White; padding-right: 0; padding-bottom: 5pt; padding-left: 0; vertical-align: bottom"><span style="text-decoration: underline solid; color: Black"><b>Stage</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; text-align: center; width: 19%; padding-right: 0; padding-bottom: 5pt; padding-left: 0; vertical-align: bottom"><span style="color: Black">Implied
    Enterprise <br/>
    Value ($m*)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">7/29/2024</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Nerio
    Therapeutics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Boehringer
    Ingelheim</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Pre-clinical</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">1,300.0</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">5/02/2024</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Mariana
    Oncology</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Novartis</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Pre-clinical</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">1,000.0</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">4/03/2024</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Kinnate
    Biopharma</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">XOMA
    Royalty Corp.</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    I</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">115.3</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">11/22/2023</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">T3
    Pharma</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Boehringer
    Ingelheim</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    I</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">509.0</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">1/16/2023</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Neogene</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">AstraZeneca</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Pre-clinical</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">200.0</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">9/07/2022</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Good
    Therapeutics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Roche</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Pre-clinical</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">250.0</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">12/10/2021</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">NBE
    Therapeutics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Boehringer
    Ingelheim</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    I</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">1,180.0</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">1/23/2020</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Synthorx</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Sanofi</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Pre-clinical</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">2,350.0</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">5/31/2018</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">AurKa
    Pharma</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">Eli
    Lilly</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="text-decoration: underline solid; color: Black"><b>Phase
    I</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="color: Black">110.0</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline; color: Black"><b>*Enterprise
value excludes contingent milestone payments when disclosure allowed.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The disclosure under the heading &#8220;<i>Selected
Precedent Reverse Merger Transactions</i>&#8221; is hereby amended and supplemented by replacing the table on page 140 and carrying over
through page 142 of the Form S-4 in its entirety with the following:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; background-color: White; vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif">Closed<br/>
    Date</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif">Surviving
    <br/>
    Company (Private)</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Public
    Vehicle<br/>
    (Ticker)</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Public
    Co. <br/>
    Cash at Close<br/>
    ($ mm)</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Value<br/>
    Delivered<br/>
    Net of<br/>
    Cash<br/>
    ($ mm)</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Public
    Co.<br/>
    %<br/>
    Ownership<br/>
    of NewCo</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Equity<br/>
    Value at<br/>
    Merger<br/>
    ($ mm)</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Enterprise<br/>
    Value at<br/>
    Merger<br/>
    ($ mm)</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Concurrent<br/>
    ($ mm)</b></span></td></tr>
  <tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; width: 13%; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">10
    / 17 / 2024</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; width: 17%; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">TuHURA
    Biosciences</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; width: 22%; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Kintara
    Therapeutics (KTRA)</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; width: 8%; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>1</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; width: 8%; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">10</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; width: 8%; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>6
    %</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; width: 8%; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>191</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; width: 8%; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>160</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; width: 8%; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>31</b></span></td>
    </tr>
  <tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">10
    / 09 / 2024</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Wex
    Pharmaceuticals (&#8220;Dogwood&#8221;)</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Virios
    Therapeutics (VIRI)</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>0</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">6</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>6
    %</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>99</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>99</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>20</b></span></td>
    </tr>
  <tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">08
    / 29 / 2024</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Oruka
    Therapeutics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>ARCA
    Biopharma (ABIO)</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>5</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">6</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>2
    %</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>450</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>175</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>275</b></span></td>
    </tr>
  <tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">08
    / 12 / 2024</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Firefly
    Neurosciences</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>WaveDancer
    (WAVD)</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>1</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">14</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>8
    %</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>110</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>110</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>4</b></span></td>
    </tr>
  <tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">06
    / 20 / 2024</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Tetonic
    Therapeutic</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>AVROBIO
    (AVRO)</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>65</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">13</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>25
    %</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>140</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>140</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>131</b></span></td>
    </tr>
  <tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">04
    / 01 / 2024</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Tawsfynydd
    Therapeutics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Onconova
    Therapeutics (ONTX)</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>7</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">11</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>14
    %</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>100</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>104</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>14</b></span></td>
    </tr>
  <tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">03
    / 26 / 2024</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Serina
    Therapeutics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>AgeX
    Therapeutics (AGE)</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>24</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">6</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>25
    %</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>90</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>83</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>15</b></span></td>
    </tr>
  <tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">03
    / 25 / 2024</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Q32
    Bio</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Homology
    Medicines (FIXX)</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>60</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">20</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>26
    %</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>195</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>195</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>42</b></span></td>
    </tr>
  <tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">03
    / 21 / 2024</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">LENZ
    Therapeutics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Graphite
    Bio (GRPH)</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>115</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">12</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>31
    %</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>232</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>232</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>54</b></span></td>
    </tr>
  <tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">03
    / 14 / 2024</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Immunogenx
    (Entero Tx)</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>First
    Wave BioPharma (FWBI)</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>4</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">15</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>18
    %</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>85</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>95</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>&#8212;</b></span></td>
    </tr>
  <tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">03
    / 06 / 2024</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Adaptive
    Phage Therapeutics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>BiomX
    (PHGE)</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>N/A</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">N/A</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>55
    %</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>N/A</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>N/A</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>50</b></span></td>
    </tr>
  <tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">12
    / 27 / 2023</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Cyclo
    Therapeutics</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Applied
    Molecular Transport (AMTI)</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>12</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">1</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>25
    %</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>41</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>28</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>&#8212;</b></span></td>
    </tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 13%"><span style="font-family: Times New Roman, Times, Serif">Closed<br/>
    Date</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; background-color: White; vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 17%"><span style="font-family: Times New Roman, Times, Serif">Surviving
    <br/>
    Company (Private)</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 22%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Public
    Vehicle<br/>
    (Ticker)</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Public
    Co. <br/>
    Cash at Close<br/>
    ($ mm)</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; background-color: White; vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; color: Black">Value<br/>
    Delivered<br/>
    Net of<br/>
    Cash<br/>
    ($ mm)</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Public
    Co.<br/>
    %<br/>
    Ownership<br/>
    of NewCo</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Equity<br/>
    Value at<br/>
    Merger<br/>
    ($ mm)</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Enterprise<br/>
    Value at<br/>
    Merger<br/>
    ($ mm)</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Concurrent<br/>
    ($ mm)</b></span></td></tr>

<tr>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 13%"><span style="font-family: Times New Roman, Times, Serif; color: Black">12
    / 18 / 2023</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 17%"><span style="font-family: Times New Roman, Times, Serif; color: Black">Neurogene</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 22%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Neoleukin
    Therapeutics (NLTX)</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>42</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; color: Black">14</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>16
    %</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>295</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>200</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>95</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">12
    / 15 / 2023</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">ProteoMedix
    (Onconetix)</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Blue
    Water Biotech (BWV)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>N/A</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">N/A</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>20
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>75</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>52</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>&#8212;</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">11
    / 13 / 2023</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Cartesian
    Therapeutics</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Selecta
    Biosciences (RNAC)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>50</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">13</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>27
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>170</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>170</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>60</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">11
    / 03 / 2023</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Korro
    Bio</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Frequency
    Therapeutics (FREQ)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>25</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">15</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>8
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>326</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>298</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>117</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">10
    / 31 / 2023</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Lung
    Therapeutics</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Aileron
    Therapeutics (ALRN)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>8</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">10</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>17
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>90</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>90</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>18</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">10
    / 16 / 2023</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Notable
    Labs</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Vascular
    Biogenics (VBLT)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>15</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">20</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>25
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>110</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>95</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>10</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">09
    / 11 / 2023</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Dianthus
    Therapeutics</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Magenta
    Therapeutics (MGTA)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>65</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">20</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>22
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>225</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>225</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>70</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">08
    / 16 / 2023</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">EIP
    Pharma (CervoMed)</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Diffusion
    Pharmaceuticals (DFFN)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>12</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">10</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>22
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>79</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>79</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>&#8212;</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">06
    / 29 / 2023</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">TeraImmune</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Baudax
    Bio (BXRX)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>N/A</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">3</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>18
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>10</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>10</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>&#8212;</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">06
    / 22 / 2023</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Spyre
    Therapeutics</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Aeglea
    BioTherapeutics (AGLE)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>10</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">25</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>5
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>110</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>110</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>210</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">06
    / 01 / 2023</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Elicio
    Therapeutics</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Angion
    Biomedica (ANGN)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>27</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">7</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>35
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>95</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>95</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>&#8212;</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">04
    / 22 / 2023</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">GRI
    Bio</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Vallon
    Pharmaceuticals (VLON)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>&#8212;</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">29</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>17
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>65</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>49</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>15</b></span></td>
    </tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: black 1pt solid; vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 13%"><span style="font-family: Times New Roman, Times, Serif">Closed<br/>
    Date</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 17%"><span style="font-family: Times New Roman, Times, Serif">Surviving
    <span style="color: Black"><br/>
    Company (Private)</span></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 22%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Public
    Vehicle<br/>
    (Ticker)</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Public
    Co. <br/>
    Cash at Close<br/>
    ($ mm)</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; color: Black">Value<br/>
    Delivered<br/>
    Net of<br/>
    Cash<br/>
    ($ mm)</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Public
    Co.<br/>
    %<br/>
    Ownership<br/>
    of NewCo</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Equity<br/>
    Value at<br/>
    Merger<br/>
    ($ mm)</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Enterprise<br/>
    Value at<br/>
    Merger<br/>
    ($ mm)</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Concurrent<br/>
    ($ mm)</b></span></td></tr>

<tr>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 13%"><span style="font-family: Times New Roman, Times, Serif; color: Black">03
    / 20 / 2023</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 17%"><span style="font-family: Times New Roman, Times, Serif; color: Black">CalciMedica</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 22%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Graybug
    Vision (GRAY)</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>25</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; color: Black">15</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>28
    %</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>100</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>100</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>10</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">03
    / 07 / 2023</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Carisma
    Therapeutics</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Sesen
    Bio (SESN)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>110</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">15</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>25
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>196</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>196</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>30</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">02
    / 23 / 2023</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Enliven
    Therapeutics</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Imara
    (IMRA)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>82</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">10</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>16
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>489</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>325</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>165</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">01
    / 09 / 2023</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Catheter
    Precision</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Ra
    Medical Systems (RMED)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>6</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">4</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>12
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>62</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>63</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>9</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">12
    / 29 / 2022</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Disc
    Medicine</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Gemini
    Therapeutics (GMTX)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>90</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">10</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>26
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>314</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>260</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>54</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">12
    / 27 / 2022</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">GNI
    Group (Gyre Tx)</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Catalyst
    Biosciences (CBIO)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>1</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">9</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>3
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>334</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>333</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>&#8212;</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">12
    / 19 / 2022</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Kineta,
    Inc.</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Yumanity
    Therapeutics (YMTX)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>8</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">26</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>15
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>194</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>194</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>30</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">11
    / 08 / 2022</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">ARS
    Pharmaceuticals</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Silverback
    Therapeutics (SBTX)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>265</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">5</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>38
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>441</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>426</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>&#8212;</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">09
    / 28 / 2022</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Aceragen,
    Inc.</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Idera
    Pharmaceuticals (IDRA)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>21</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">7</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>33
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>57</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>42</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>&#8212;</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">09
    / 15 / 2022</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Lisata
    Therapeutics (Cend)</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Caladrius
    Biosciences (CLBS)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>65</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">25</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>50
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>90</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>84</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>&#8212;</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">08
    / 30 / 2022</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Vivani
    Medical</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Second
    Sight Medical (EYES)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>55</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">N/A</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>23
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>141</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>131</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>&#8212;</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">07
    / 05 / 2022</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Syros
    Pharmaceuticals</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Tyme
    Technologies (TYME)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>62</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">8</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>27
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>189</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>141</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>130</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">05
    / 16 / 2022</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Aprea
    Therapeutics</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Atrin
    Pharmaceuticals (APRE)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>35</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">15</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>41
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>75</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>75</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>&#8212;</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">10
    / 24 / 2021</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Quoin
    Pharmaceuticals</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Cellect
    Biotechnology (APOP)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>5</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">13</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>25
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>56</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>51</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>22</b></span></td>
    </tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 13%"><span style="font-family: Times New Roman, Times, Serif">Closed<br/>
    Date</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; background-color: White; vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 17%"><span style="font-family: Times New Roman, Times, Serif">Surviving
    <br/>
    Company (Private)</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 22%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Public
    Vehicle<br/>
    (Ticker)</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Public
    Co. <br/>
    Cash at Close<br/>
    ($ mm)</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; background-color: White; vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; color: Black">Value<br/>
    Delivered<br/>
    Net of<br/>
    Cash<br/>
    ($ mm)</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Public
    Co.<br/>
    %<br/>
    Ownership<br/>
    of NewCo</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Equity<br/>
    Value at<br/>
    Merger<br/>
    ($ mm)</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Enterprise<br/>
    Value at<br/>
    Merger<br/>
    ($ mm)</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Concurrent<br/>
    ($ mm)</b></span></td></tr>

<tr>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 13%"><span style="font-family: Times New Roman, Times, Serif; color: Black">08
    / 26 / 2021</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 17%"><span style="font-family: Times New Roman, Times, Serif; color: Black">Aadi
    Bioscience</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 22%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Aerpio
    Pharmaceuticals (ARPO)</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>28</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; color: Black">15</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>52
    %</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>82</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>79</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>155</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">08
    / 03 / 2021</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Decoy
    Biosystems</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Indaptus
    Therapeutics (INDP)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>2</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">10</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>34
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>65</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>35</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>30</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">07
    / 27 / 2021</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Cytocom
    (Statera)</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Cleveland
    BioLabs (CBLI)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>3</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">N/A</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>39
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>61</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>61</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>&#8212;</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">06
    / 28 / 2021</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Tempest
    Therapeutics</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Millendo
    Therapeutics (MLND)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>17</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">19</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>23
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>158</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>128</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>30</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">06
    / 15 / 2021</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">ReShape
    Lifesciences</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Obalon
    Therapeutics (OBLN)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>4</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">15</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>49
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>19</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>28</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>&#8212;</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">04
    / 27 / 2021</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Leading
    BioSciences (Palisade)</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Seneca
    Biopharma (SNCA)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>5</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">30</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>35
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>98</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>78</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>20</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">04
    / 16 / 2021</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">MyMD
    Pharmaceuticals</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Akers
    Biosciences (AKER)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>23</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">5</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>20
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>269</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>251</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>18</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">03
    / 31 / 2021</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">StemoniX
    (Vyant Bio)</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Cancer
    Genetics (CGIX)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>2</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">15</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>22
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>60</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>60</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>&#8212;</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">03
    / 16 / 2021</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">ChemomAb
    Ltd.</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Anchiano
    Therapeutics (ANCN)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>0</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">15</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>10
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>135</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>90</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>46</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">02
    / 24 / 2021</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Viracta
    Therapeutics</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Sunesis
    Pharmaceuticals (SNSS)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>14</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">16</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>14
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>185</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>120</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>65</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">01
    / 28 / 2021</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Quellis
    Biosciences (Astria)</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Catabasis
    Pharmaceuticals (CATB)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>37</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">25</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>25
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>185</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>177</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>110</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">12
    / 22 / 2020</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Yumanity
    Therapeutics</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Proteostasis
    Therapeutics (PTI)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>29</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">34</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>29
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>154</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>120</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>34</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">12
    / 01 / 2020</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Petros
    Pharmaceuticals</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Neurotrope
    (NTRP)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>N/A</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">4</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>&#8212;</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>N/A</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>N/A</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>&#8212;</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">11
    / 23 / 2020</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">F-star
    Therapeutics</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Spring
    Bank Pharmaceuticals</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>11</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">23</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>46
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>40</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>25</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>15</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">11
    / 05 / 2020</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Ocuphire
    Pharma</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Rexahn
    Pharmaceuticals (REXN)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>2</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">16</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>13
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>138</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>117</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>21</b></span></td>
    </tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: black 1pt solid; vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 13%"><span style="font-family: Times New Roman, Times, Serif">Closed<br/>
    Date</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 17%"><span style="font-family: Times New Roman, Times, Serif">Surviving
    <br/>
    Company (Private)</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 22%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Public
    Vehicle<br/>
    (Ticker)</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Public
    Co. <br/>
    Cash at Close<br/>
    ($ mm)</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; color: Black">Value<br/>
    Delivered<br/>
    Net of<br/>
    Cash<br/>
    ($ mm)</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Public
    Co.<br/>
    %<br/>
    Ownership<br/>
    of NewCo</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Equity<br/>
    Value at<br/>
    Merger<br/>
    ($ mm)</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Enterprise<br/>
    Value at<br/>
    Merger<br/>
    ($ mm)</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Concurrent<br/>
    ($ mm)</b></span></td></tr>

<tr>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 13%"><span style="font-family: Times New Roman, Times, Serif; color: Black">10
    / 27 / 2020</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 17%"><span style="font-family: Times New Roman, Times, Serif; color: Black">Viridian
    Therapeutics</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 22%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Miragen
    Therapeutics (MGEN)</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>12</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; color: Black">15</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>12
    %</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>191</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>71</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>91</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">09
    / 15 / 2020</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Adicet
    Bio</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>resTORbio
    (TORC)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>65</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">8</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>25
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>220</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>220</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>&#8212;</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">09
    / 14 / 2020</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Anelixis
    Therapeutics (Eledon)</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Novus
    Therapeutics (NVUS)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>5</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">5</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>5
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>183</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>75</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>108</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">07
    / 06 / 2020</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Kiq
    Bio (Cogent)</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Unum
    Therapeutics (UMRX)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>12</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">17</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>16
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>149</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>45</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>104</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">06
    / 15 / 2020</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Forte
    Biosciences</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Tocagen
    (TOCA)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>1</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">8</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>14
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>49</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>30</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>19</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">05
    / 28 / 2020</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Larimar
    Therapeutics</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Zafgen
    (ZFGN)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>40</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">5</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>23
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>148</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>68</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>80</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">05
    / 26 / 2020</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Histogen,
    Inc.</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Conatus
    Pharmaceuticals (CNAT)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>13</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">23</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>26
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>100</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>100</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>&#8212;</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">05
    / 22 / 2020</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Qualigen,
    Inc.</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Ritter
    Pharmaceuticals (RTTR)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>N/A</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">N/A</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>8
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>N/A</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>N/A</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>4</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">05
    / 18 / 2020</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Timber
    Pharmaceuticals</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>BioPharmX
    Corporation (BPMX)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>2</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">16</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>12
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>106</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>86</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>20</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">04
    / 01 / 2020</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Curetis
    NV</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>OpGen
    (OPGN)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>7</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">7</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>28
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>24</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>24</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>9</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">01
    / 09 / 2020</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Protara
    Therapeutics</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Proteon
    Therapeutics (PRTO)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>3</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">5</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>10
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>63</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>20</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>43</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">12
    / 30 / 2019</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">NeuroBo
    Pharmaceuticals</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Gemphire
    Therapeutics (GEMP)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>8</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">4</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>4
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>118</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>94</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>24</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">11
    / 07 / 2019</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Venus
    Concept</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Restoration
    Robotics (HAIR)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>10</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">20</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>15
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>223</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>282</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>21</b></span></td>
    </tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 13%"><span style="font-family: Times New Roman, Times, Serif">Closed<br/>
    Date</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; background-color: White; vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 17%"><span style="font-family: Times New Roman, Times, Serif">Surviving
    <br/>
    Company (Private)</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 22%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Public
    Vehicle<br/>
    (Ticker)</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Public
    Co. <br/>
    Cash at Close<br/>
    ($ mm)</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; background-color: White; vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; color: Black">Value<br/>
    Delivered<br/>
    Net of<br/>
    Cash<br/>
    ($ mm)</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Public
    Co.<br/>
    %<br/>
    Ownership<br/>
    of NewCo</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Equity<br/>
    Value at<br/>
    Merger<br/>
    ($ mm)</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Enterprise<br/>
    Value at<br/>
    Merger<br/>
    ($ mm)</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; vertical-align: bottom; text-align: center; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Concurrent<br/>
    ($ mm)</b></span></td></tr>

<tr>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 13%"><span style="font-family: Times New Roman, Times, Serif; color: Black">09
    / 27 / 2019</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 17%"><span style="font-family: Times New Roman, Times, Serif; color: Black">Ocugen,
    Inc.</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 22%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Histogenics
    Corporation (HSGX)</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>N/A</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; color: Black">N/A</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>17
    %</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>N/A</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>N/A</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>25</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">08
    / 31 / 2019</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Brickell
    Biotech</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Vical
    Incorporated (VICL)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>35</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">4</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>44
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>50</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>50</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>25</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">07
    / 31 / 2019</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">ESSA
    Pharma</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Realm
    Therapeutics (RLM)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>21</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">1</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>46
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>45</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>45</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>36</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">07
    / 22 / 2019</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Salarius
    Pharmaceuticals</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Flex
    Pharma (FLKS)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>7</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">4</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>20
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>36</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>30</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>6</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">07
    / 15 / 2019</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">NeuBase
    Therapeutics</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Ohr
    Pharmaceutical (OHRP)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>1</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">7</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>15
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>41</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>32</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>9</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">06
    / 10 / 2019</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Oncternal
    Therapeutics</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>GTx
    (GTXI)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>15</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">9</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>23
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>81</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>77</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>&#8212;</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">06
    / 09 / 2019</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Edesa
    Biotech</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Stellar
    Biotechnologies (SBOT)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>4</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">2</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>12
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>42</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>37</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>&#8212;</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">05
    / 09 / 2019</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Armata
    Pharmaceuticals</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Ampliphi
    Biosciences (APHB)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>2</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">10</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>24
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>28</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>22</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>10</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">05
    / 06 / 2019</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Adynxx,
    Inc.</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Alliqua
    BioMedical (ALQA)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>2</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">3</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>14
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>29</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>21</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>&#8212;</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">04
    / 23 / 2019</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Mereo
    BioPharma</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Oncomed
    Pharmaceuticals (OMED)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>37</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">20</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>26
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>222</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>213</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>&#8212;</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">04
    / 12 / 2019</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Immunic
    AG</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Vital
    Therapies (VTL)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>7</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">10</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>12
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>85</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>79</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>30</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">03
    / 26 / 2019</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Enlivex
    Therapeutics</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Bioblast
    Pharma (ORPN)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>0</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">5</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>4
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>108</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>100</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>8</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">03
    / 18 / 2019</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">PDS
    Biotechnology</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Edge
    Therapeutics (EDGE)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>25</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">5</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>30
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>70</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>70</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>&#8212;</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">03
    / 13 / 2019</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">X4
    Pharmaceuticals</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Arsanis
    (ASNS)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>21</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">29</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>30
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>115</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>115</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>&#8212;</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">01
    / 24 / 2019</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Seelos
    Therapeutics</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Apricus
    Biosciences (APRI)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>3</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">8</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>14
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>65</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>65</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>18</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">12
    / 07 / 2018</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Millendo
    Therapeutics</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>OvaScience
    (OVAS)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>36</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">5</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>17
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>155</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>155</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>50</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">10
    / 12 / 2018</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Aravive
    Biologics</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Versartis
    (VSAR)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>57</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">0</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>50
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>54</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>50</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>&#8212;</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">02
    / 13 / 2018</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Vaxart,
    Inc.</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Aviragen
    Therapeutics (AVIR)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>30</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">44</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>49
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>77</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>77</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>&#8212;</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">01
    / 30 / 2018</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Innovate
    Biopharmaceuticals</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Monster
    Digital (MSDI)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>0</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">6</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>9
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>60</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>60</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>21</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">01
    / 17 / 2018</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Evofem
    Biosciences</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Neothetics
    (NEOT)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>0</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">29</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>13
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>171</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>151</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>20</b></span></td>
    </tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">01
    / 04 / 2018</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">Rocket
    Pharmaceuticals</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>Inotek
    Pharmaceuticals (ITEK)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>42</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; background-color: White; vertical-align: top; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; color: Black">5</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>19
    %</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>200</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>N/A</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; background-color: White; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid; color: Black"><b>&#8212;</b></span></td>
    </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="color: #212529"><b>Forward-Looking Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This communication contains
forward-looking statements (including within the meaning of Section&#160;21E of the Exchange Act and Section&#160;27A of the Securities
Act) concerning GlycoMimetics, Crescent, the proposed transactions and other matters. These forward-looking statements include express
or implied statements relating to the structure, timing and completion of the proposed Merger; the combined company&#8217;s listing on
Nasdaq after closing of the proposed Merger; expectations regarding the ownership structure of the combined company; the expected executive
officers and directors of the combined company; each company&#8217;s and the combined company&#8217;s expected cash position at the closing
of the proposed Merger (including completion of Crescent&#8217;s pre-closing financing) and cash runway of the combined company; the
future operations of the combined company; the nature, strategy and focus of the combined company; the development and commercial potential
and potential benefits of any product candidates of the combined company; anticipated preclinical and clinical drug development activities
and related timelines, including the expected timing for data and other clinical results; the combined company having sufficient resources
to advance its pipeline candidates; and other statements that are not historical fact. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221;
&#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intends,&#8221;
&#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221;
&#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions (including the negatives of these terms or variations
of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects.
There can be no assurance that future developments affecting GlycoMimetics, Crescent or the proposed transaction will be those that have
been anticipated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The forward-looking
statements contained in this communication are based on current expectations and beliefs concerning future developments and their potential
effects and therefore subject to other risks and uncertainties. These risks and uncertainties include, but are not limited to, risks
associated with the possible failure to satisfy the conditions to the closing or consummation of the Merger, including GlycoMimetics&#8217;
failure to obtain stockholder approval for the Merger, risks associated with the potential failure to complete the financing transaction
in a timely manner or at all, risks associated with the uncertainty as to the timing of the consummation of the Merger and the ability
of each of GlycoMimetics and Crescent to consummate the transactions contemplated by the Merger, risks associated with GlycoMimetics&#8217;
continued listing on Nasdaq until closing of the Merger, the failure or delay in obtaining required approvals from any governmental or
quasi-governmental entity necessary to consummate the Merger; the occurrence of any event, change or other circumstance or condition
that could give rise to the termination of the Merger prior to the closing or consummation of the Merger, risks associated with the possible
failure to realize certain anticipated benefits of the Merger, including with respect to future financial and operating results; the
effect of the completion of the Merger on the combined company&#8217;s business relationships, operating results and business generally;
risks associated with the combined company&#8217;s ability to manage expenses and unanticipated spending and costs that could reduce
the combined company&#8217;s cash resources; risks related to the combined company&#8217;s ability to correctly estimate its operating
expenses and other events; changes in capital resource requirements; risks related to the inability of the combined company to obtain
sufficient additional capital to continue to advance its product candidates or its preclinical programs; the outcome of any legal proceedings
that may be instituted against the combined company or any of its directors or officers related to the Merger Agreement or the transactions
contemplated thereby; the ability of the combined company to obtain, maintain and protect its intellectual property rights, in particular
those related to its product candidates; the combined company&#8217;s ability to advance the development of its product candidates or
preclinical activities under the timelines it anticipates in planned and future clinical trials; the combined company&#8217;s ability
to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates;
the combined company&#8217;s ability to realize the anticipated benefits of its research and development programs, strategic partnerships,
licensing programs or other collaborations; regulatory requirements or developments and the combined company&#8217;s ability to obtain
necessary approvals from the U.S. Food and Drug Administration or other regulatory authorities; changes to clinical trial designs and
regulatory pathways; competitive responses to the Merger and changes in expected or existing competition; unexpected costs, charges or
expenses resulting from the Merger; potential adverse reactions or changes to business relationships resulting from the completion of
the Merger; legislative, regulatory, political and economic developments; and those risks and uncertainties and other factors more fully
described in filings with the SEC, including the Form S-4 and reports filed on Form&#160;10-K,&#160;10-Q&#160;and&#160;8-K&#160;and in
other filings made by GlycoMimetics with the SEC from time to time and available at www.sec.gov. These forward-looking statements are
based on current expectations, and with regard to the proposed transaction, are based on GlycoMimetics&#8217; current expectations, estimates
and projections about the expected date of closing of the proposed transaction and the potential benefits thereof, its business and industry,
management&#8217;s beliefs and certain assumptions made by GlycoMimetics, all of which are subject to change. Such forward-looking statements
are made as of the date of this release, and the parties undertake no obligation to update such statements to reflect subsequent events
or circumstances, except as otherwise required by securities and other applicable law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>No Offer or Solicitation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Current Report on Form 8-K is not intended
to and does not constitute (i)&#160;a solicitation of a proxy, consent or approval with respect to any securities or in respect of the
proposed transaction or (ii)&#160;an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase
or subscribe for any securities pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer
of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus
meeting the requirements of the Securities Act or an exemption therefrom. Subject to certain exceptions to be approved by the relevant
regulators or certain facts to be ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction
where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality
(including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility
of a national securities exchange, of any such jurisdiction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION
HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS COMMUNICATION IS TRUTHFUL OR COMPLETE.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Important Additional Information About the
Proposed Transaction </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Current Report on Form 8-K does not substitute
for the Form S-4, proxy statement/prospectus or for any other document that GlycoMimetics has filed or may file with the SEC in connection
with the proposed transaction. In connection with the proposed transaction between GlycoMimetics and Crescent, GlycoMimetics has filed
relevant materials with the SEC, including the Form S-4 that contains a proxy statement/prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">GLYCOMIMETICS URGES INVESTORS AND STOCKHOLDERS
TO READ THE FORM S-4, PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT HAVE BEEN OR MAY BE FILED WITH THE SEC, AS WELL
AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN
OR WILL CONTAIN IMPORTANT INFORMATION ABOUT GLYCOMIMETICS, CRESCENT, THE PROPOSED TRANSACTION AND RELATED MATTERS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investors and stockholders can obtain free copies
of the Form S-4 and other documents filed by GlycoMimetics with the SEC (when they become available) through the website maintained by
the SEC at www.sec.gov. In addition, investors and stockholders should note that GlycoMimetics communicates with investors and the public
using its website (www.glycomimetics.com) and the investor relations website (www.glycomimetics.com/investor-relations) where anyone
is able to obtain free copies of the Form S-4 and other documents filed by GlycoMimetics with the SEC and stockholders are urged to read
the Form S-4 and the other relevant materials when they become available before making any voting or investment decision with respect
to the proposed transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Participants in the Solicitation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">GlycoMimetics, Crescent and their respective
directors and executive officers may be deemed to be participants in the solicitation of proxies from stockholders in connection with
the proposed transaction. Information about GlycoMimetics&#8217; directors and executive officers including a description of their interests
in GlycoMimetics is included in GlycoMimetics&#8217; Annual Report on Form 10-K, as filed with the SEC on February 13, 2025, and in subsequent
reports filed with the SEC. Additional information regarding these persons and their interests in the proposed transaction are included
in the Form S-4 relating to the proposed transaction filed with the SEC. These documents can be obtained free of charge from the sources
indicated above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2">GlycoMimetics, Inc.</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2">(Registrant)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 50%">Date: May 30, 2025</td>
    <td style="width: 3%">By:</td>
    <td style="border-bottom: black 1pt solid; width: 47%">&#8239;/s/ Brian Hahn</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>Brian Hahn</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>Principal Financial Officer</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 14; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6PbQrKrJLhw5xigwRb6uLUtyakda/R/ItrRtiCITknC9HiFjktDA1MhxmZQE7bNpae4QSz8hoTxgc2XKVQpglXozzrK3v1h+YUWAwMJOBPIZ757wbh1UKcjRU06Eag1TpaALbtYi+ekb2bCq03ugatK1gy9SyQa/51X/Y6SdZal5d0h7ZGbIpJAPZy29QMlGwobt+EF8dFEUmorirSORMtza45k+P9kvCvMYmxLme/nf0Ac5GSmE= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>2
<FILENAME>glyc-20250530.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaiPebOdzZR+6YkxtmBybenaDyMt4r9P1Cdq6eDG4Q0D -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:GLYC="http://glycomimetics.com/20250530" elementFormDefault="qualified" targetNamespace="http://glycomimetics.com/20250530">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://glycomimetics.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="glyc-20250530_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="glyc-20250530_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>3
<FILENAME>glyc-20250530_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>4
<FILENAME>glyc-20250530_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://glycomimetics.com/role/Cover" xlink:href="glyc-20250530.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://glycomimetics.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 30,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GlycoMimetics,
Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001253689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1686563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">P.O.
Box 65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Monrovia<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">21770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">243-1201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GLYC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2516580d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glycomimetics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>glyc-20250530.xsd</File>
    <File>glyc-20250530_lab.xml</File>
    <File>glyc-20250530_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2516580d1_8k.htm">tm2516580d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>12
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2516580d1_8k.htm": {
   "nsprefix": "GLYC",
   "nsuri": "http://glycomimetics.com/20250530",
   "dts": {
    "schema": {
     "local": [
      "glyc-20250530.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "glyc-20250530_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "glyc-20250530_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2516580d1_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://glycomimetics.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-05-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2516580d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-05-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2516580d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>13
<FILENAME>0001104659-25-054587-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-054587-xbrl.zip
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M9IC^.WGN/!&WB[W@835LA:2A# \5F[T^8(H8)(-\G%B7N*H;&M97R8QR=Z\
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M,UZN9?3,Y&(R"=[B'][3??6I>$@*"X$W(3(ZIGV =2FKEXY+AZ7":V#'[,5
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MR?$]$<H5J7,#L<;7K*!<,14^#GAN%@A$S!"#%8,W_Y%!ZLCO<GDT(+%P8?/
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M4#EB[6EWU'0LPW>U_QJ=[J?HX)CH1EIQ% ,:+CE#MU#8,N*L )Y<$8!I6%R
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M4-_3CY4%&^<5YGDP/K=A8U[MVU[;82^;UBW#=IIT[3NE.%;"28**98U-<2B
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ME0848=*N@6, *)E ")#,B*J##PWFMP8;!KK7$QJ,#W)%0;T$Q45& 9H;#<V
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MMM>Q3O\_4$L! A0#%     @ RT.^6A\HIK8L P  \0L  !$
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3!@     $  0 !0$  .5Z      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>tm2516580d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="glyc-20250530.xsd" xlink:type="simple"/>
    <context id="AsOf2025-05-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
        </entity>
        <period>
            <startDate>2025-05-30</startDate>
            <endDate>2025-05-30</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-05-30" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-05-30" id="Fact000004">0001253689</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-05-30" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-05-30" id="Fact000010">2025-05-30</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-05-30" id="Fact000011">GlycoMimetics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-05-30" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-05-30" id="Fact000013">001-36177</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-05-30" id="Fact000014">06-1686563</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-05-30" id="Fact000015">P.O. Box 65</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-05-30" id="Fact000016">Monrovia</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-05-30" id="Fact000017">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-05-30" id="Fact000018">21770</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-05-30" id="Fact000019">240</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-05-30" id="Fact000020">243-1201</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-05-30" id="Fact000021">true</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-05-30" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-05-30" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-05-30" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-05-30" id="Fact000025">Common     Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-05-30" id="Fact000026">GLYC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-05-30" id="Fact000027">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-05-30" id="Fact000028">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
